Jupiter Neurosciences ($JUNS) Climbed 55% After PharmAla License Deal — Scored 83/100 at 7:00 AM ET
JUNS stock climbed 55% after announcing a licensing deal with PharmAla. RTPR scored the release 83/100 at 7:00 AM ET.
Jupiter Neurosciences (NASDAQ: JUNS) stock is up today after the company announced it secured exclusive U.S. rights to PharmAla Biotech's ALA-002 compound, climbing as much as 55% from its price when the release crossed the wire. RTPR assigned the release an impact score of 83/100 at 7:00 AM ET, when the stock traded at $0.17.
What the release announced
According to the press release (free account required), PharmAla Biotech has executed a definitive license agreement granting Jupiter Neurosciences exclusive U.S. rights to ALA-002. The deal structure includes up to $100 million in upfront and milestone payments, plus royalties.
What the stock did
Following the announcement, JUNS traded from $0.17 to a session high of $0.27, a gain of approximately 55%.
Historical context
This release received an impact score of 83/100.
- Releases scoring 80-100 produced a 15%+ move 49% of the time.
- Sample size: 175 settled outcomes over the past 90 days.
- Historical observations only, not predictions. Full band-by-band table on the impact scoreboard.
Timeline
- 7:00:00 AM ET — press release crossed the wire
- +389 ms — RTPR delivered the release
- 7:00:31 AM ET — impact score written: 83/100
- $0.17 — price at publication
- $0.27 — intraday high (55% above the price at publication)
Real-time impact scores on every press release are part of RTPR Pro. Impact scores are in beta; historical tendencies, not predictions or investment advice.